Company intelligence / Profile preview

Cerecin

Denver, Colorado, United States

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Cerecin’s lead asset CER‑0001 has shown promising pilot data in migraine and infantile spasms. The company recently expanded its pipeline with CER‑022, a novel PET imaging agent to study ketone body metabolism. Their focus on neurometabolism positions them at the forefront of developing therapies that address metabolic dysfunctions underlying CNS diseases.[3][5]

Therapeutic areas: Neurology
Modalities: Small molecules (notably lipid-based therapeutics such as tricaprilin)Diagnostic radiotracers (e.g., [18F]FBHB for PET imaging)
Industry: Biotech

Drug pipeline

6 assets

tricaprilin

5 more assets in the full pipeline.

Request access →

Partnerships

Nestlé S.A.Wilmar International LimitedUniversity of Alberta (licensing partner)[4][5]

Beyond the preview

Go deeper on Cerecin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerecin.

Explore the full profile